文献速递糖尿病垂体与肾上腺疾病

帕瑞肽治疗胰岛素瘤相关低血糖的疗效与安全性

Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该系统综述检索MEDLINE、Scopus、Google Scholar及参考文献至2024年3月30日,纳入13项研究共17例胰岛素瘤相关低血糖患者,评估帕瑞肽的疗效与安全性。帕瑞肽从未作为初始治疗,6例(35%)无改善,4例(23%)部分改善,7例(41%)完全缓解;侵袭性胰岛素瘤无改善比例55%高于惰性病例的16%,较大肿瘤与较差反应显著相关(P=0.043);高血糖为最常见副作用(n=3)。

要点

  • 帕瑞肽在既往治疗失败的胰岛素瘤相关低血糖患者中可有效恢复血糖水平。
  • 侵袭性胰岛素瘤对帕瑞肽反应较低,无改善比例55% vs 惰性病例16%。
  • 较大肿瘤与较差反应显著相关(P=0.043)。

核心结论

  • 帕瑞肽对既往治疗失败的胰岛素瘤患者可有效恢复血糖水平,但在侵袭性胰岛素瘤中疗效较低,提示转移性病例需替代或联合策略。
  • 鉴于所回顾病例中帕瑞肽从未作为一线治疗,作者认为在选定患者中更早给药可能改善结局。

研究设计与样本

  • 系统综述,遵循预先制定的方案,检索MEDLINE、Scopus、Google Scholar及参考文献前后向追溯,自数据库建立至2024年3月30日。
  • 490项研究中137项被审查,最终13项研究的17例病例符合纳入标准。

主要发现

  • 患者年龄52至71岁,其中女性9例;5例(30%)接受了手术肿瘤切除。
  • 帕瑞肽从未作为初始治疗;最常见剂量为长效释放剂型40至60 mg/月,短效剂型0.6 mg/12小时。
  • 6例(35%)无改善,4例(23%)部分改善,7例(41%)完全缓解。
  • 侵袭性胰岛素瘤患者反应率较低,55%无改善,而惰性病例为16%。
  • 较大肿瘤与较差反应显著相关(P=0.043);高血糖为最常见副作用(n=3)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 帕瑞肽的使用仅在病例系列和病例报告中有报道。
  • 帕瑞肽在回顾病例中从未作为一线治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Persistent hypoglycemia is a life-threatening complication in insulinoma patients. When tumor excision is not possible, medical treatments are the main option. Pasireotide has shown promise in managing refractory hypoglycemia, but its use has been reported only in case series and reports. OBJECTIVE: This work aimed to assess the efficacy and safety of pasireotide in treating insulinoma-associated hypoglycemia. METHODS: We conducted a systematic review on using pasireotide to treat insulinoma-associated hypoglycemia, following a predeveloped protocol. We searched MEDLINE, Scopus, Google Scholar, and references forward and backward from database inception to March 30, 2024. RESULTS: Of 490 identified studies, 137 were reviewed, and 17 cases from 13 studies met the inclusion criteria. Patients' ages ranged from 52 to 71 years (9 women). Five patients (30%) underwent surgical tumor resection. Pasireotide was never the initial treatment. The most common doses were 40 to 60 mg/month for pasireotide long-acting release and 0.6 mg/12 h for short-acting pasireotide. Six patients (35%) showed no improvement, 4 (23%) had partial improvement, and 7 (41%) had complete resolution. Patients with aggressive insulinomas had a lower response rate, with 55% showing no improvement compared to 16% in indolent cases. Larger tumors were significantly associated with poorer response (P = .043). Hyperglycemia was the most common side effect (n = 3). CONCLUSION: Pasireotide effectively restored glucose levels in insulinoma patients who failed prior treatments. However, its efficacy was lower in aggressive insulinomas, emphasizing the need for alternative or combinatory strategies in metastatic cases. Given that pasireotide was never used as a first-line therapy in the reviewed cases, earlier administration in selected patients may improve outcomes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Vega-Beyhart A, Biagetti B, Marazuela M, et al. Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia. J Clin Endocrinol Metab. 2025. PMID: 40165498. doi:10.1210/clinem/dgaf195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。